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Abstract
Background: Peripherally inserted central catheters (PICCs) are commonly used for delivering intravenous therapy.
PICC failure is unacceptably high (up to 40%) due to mechanical, infectious and thrombotic complications. Poor
securement potentiates all complication types. This randomised controlled trial (RCT) aimed to examine the
feasibility of a large RCT of four dressing and securement methods to prevent PICC failure.
Methods: This single-centre pilot RCT included 124 admitted medical/surgical/cancer patients aged≥ 16 years with a
PICC. Interventions were: (i) standard polyurethane dressing and sutureless securement device (SPU + SSD, control); (ii)
polyurethane with absorbent lattice pad dressing (PAL + Tape); (iii) combination securement-dressing (CSD); and (iv)
tissue adhesive (TA + SPU). All groups except TA + SPU had a chlorhexidine-gluconate (CHG) impregnated disc.
Feasibility outcomes were recruitment and safety/acceptability of the interventions. The primary outcome was PICC
failure, a composite of PICC removal for local infection, catheter-associated bloodstream infection, dislodgement,
occlusion, and/or catheter fracture. Secondary outcomes included individual complications, dressing failure and dwell
time, PICC dwell time, skin complications/phlebitis indicators, product costs, and patient and staff satisfaction.
Qualitative feedback was also collected.
Results: PICC failure incidence was: PAL + CHG + Tape (1/5; 20%; 17.4/1000 days), SPU + SSD + CHG (control) (4/39;
10%; 9.0/1000 days), TA + SPU (3/35; 9%; 9.6/1000 days), and CSD + CHG (3/42; 7%; 9.4/1000 days). Recruitment to
PAL + CHG + Tape was ceased after five participants due to concerns of PICC dislodgement when removing the
dressing. CSD + CHG, TA + SPU (TA applied only at PICC insertion time), and control treatments were acceptable to
patients and health professionals.
Conclusion: A large RCT of CSD + CHG and TA + SPU (but not PAL + CHG + Tape) versus standard care is feasible.
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Background
Peripherally inserted central catheters (PICCs) are com-
monly used medical devices for life-saving treatment in
the hospital [1]. Generally inserted into large deep veins in
the upper periphery (basilic, brachial, cephalic, axillary),
they are threaded to the superior vena cava for blood sam-
pling, medications, fluids, nutrition, and blood transfusion
[2]. PICCs suit prolonged and/or frequent therapy, vesi-
cant chemotherapy, and irritant infusions, especially in pa-
tients with limited veins [3].
Despite their critical role, PICC failure rates are un-
acceptably high (up to 40%), interrupting therapy [4–7] due
to mechanical, infectious, and thrombotic complications.
Catheter migration (movement of the device from its central
placement) is a key clinical concern that can potentially
result in infiltration and extravasation. Thrombosis is also a
major issue, causing pain and risk of embolus [8]. Such
scenarios can lead to infiltration or accidental dislodgement
of the catheter. Catheter-associated bloodstream infection
(CABSI) is a serious health-care-associated infection that
can potentially result in septic embolism, infective endocar-
ditis, osteomyelitis, septic arthritis, and death [9–11]. Fur-
thermore, PICC failures cause negative patient experiences,
including painful repeated needle-sticks, and increases in
hospital length of stay, equipment costs, and workloads [12].
Dressing and securement methods are integral in pre-
venting PICC failure and complications, yet current dress-
ings are often inadequate [13]. Effective methods should
prevent PICCs from dislodging or migrating, and provide a
protective barrier from microbial colonisation and infec-
tion. Good dressing and securement methods also minim-
ise micro-motion, risk of vein thrombosis, and PICC
fracture (or other damage to the PICC). There are a num-
ber of dressing and securement devices available for PICCs
[13, 14], and there are variable applications within clinical
practice [13]. A recent Cochrane review [14] of 22 ran-
domised controlled trials (RCTs) (n = 7436 patients with
central venous access devices (CVADs)) found medication-
impregnated dressing products to be more effective than
non-medicated dressings to prevent catheter-related blood-
stream infections (CRBSI). However, only five of the in-
cluded trials studied PICCs, most were conducted in
intensive care units (ICUs), and many dressing products
had no evidence or low-quality evidence on effectiveness,
thus high uncertainty remains. The authors concluded that
high-quality research is required to assess the effectiveness
of novel products [14]. This study aimed to provide feasibil-
ity data for a fully powered RCT comparing standard care
versus three innovative dressing and securement methods
for PICCs in adult patients receiving acute care.
Methods
Study location
This trial was conducted at the Royal Brisbane and
Women’s Hospital (RBWH), the largest quaternary refer-
ral hospital in Queensland, Australia.
Patients and procedures
Patients were recruited from March 2014 to March
2015. Inclusion criteria were ≥ 16 years of age; planned
for PICC insertion; expected inpatient stay >24 hours;
and informed consent. Exclusions were current blood-
stream infection (BSI) (within 48 hours) at time of PICC
insertion; non-English speaking without an interpreter;
diseased, burned or scarred skin; skin tear or “paper”
skin at the insertion site; allergy to any study product;
enrolled in a competing CVAD study or previously en-
rolled in this study. ICU patients were not studied as
PICCs are rarely used in Australian ICUs. We aimed to
recruit 30 participants per arm to provide estimates of
relative treatment effects and assess protocol feasibility
[15, 16]. Initially, only patients with cancer were targeted
and only pre-PICC insertion consent requested but re-
cruitment was slow due to: (1) the size of the potential
recruitment pool; (2) urgent insertions without time to
request consent for the study; (3) unpredictable changes
in scheduling of PICC insertions; and (4) patients having
PICCs inserted in two hospital departments at the same
time, meaning the research nurse was not always
present. After 2 weeks, we extended the trial to medical
and surgical departments, and extended the recruitment
window to 24 hours post PICC insertion if no PICC
complications had occurred (in these patients, the ori-
ginal dressing was carefully removed and replaced with
the randomised dressing). The ethics committee ap-
proved this amendment.
Recruitment, randomization, allocation concealment, and
blinding
Research Nurses (ReNs) screened patients daily using a
screening log, gained informed consent, and performed
randomization after consent. A centralized web-based
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service maintained allocation concealment and randomised
participants in a 1:1:1:1 ratio between the four groups, with
block sizes randomly varied as blocks of 4 or 8 (https://
www151.griffith.edu.au/ctcc). Patients, clinical staff or ReNs
were not blinded due to the nature of the intervention.
However, the infectious diseases physician classifying
CABSI and local infection outcomes was blinded. Other
outcomes (e.g. dislodgement) were assigned by clinical, not
research staff or investigators, using routine clinical prac-
tices and documentation, which minimised the risk of bias
influencing outcomes. A Study Manager trained and super-
vised the ReNs, and undertook quality checks on data col-
lected. There was a 54-week recruitment period, with a
maximum 4-week follow-up period from insertion (or earl-
ier if the device removed or the patient was discharged).
Ethical considerations
The RBWH Human Research Ethics Committee (HREC)
(HREC/13QRBW/454) and the Griffith University HREC
(NRS/10/14/HREC) approved the study on 10 February and
20 February 2014, respectively. The trial was registered with
the Australian and New Zealand Clinical Trials Registry:
ACTRN12616000027415. All products were registered with
the Australian Therapeutic Goods Administration. Adverse
events (i.e. skin complications: any rash, blister, itchiness,
skin tear, or bruising) were recorded. Serious adverse events
(e.g. BSI, ICU admissions, or death) were reported to the
HREC. Written informed consent was obtained from partici-
pants/substitute decision-makers or the next of kin for those
younger than 18 years of age. Each participant, substitute
decision-maker or next of kin was provided with ample time
to read and consider the participant information sheet before
signing the consent form. Informed consent and signature
was witnessed by an independent party and the ReN.
Study groups
Group 1 (control): received a standard polyurethane dressing
(SPU) [17–21] (IV3000™ - Standard 10 cm x 14 cm [Product
ID: 18477493]; Smith and Nephew, Hull, UK) and a sutureless
securement device (SSD) (StatLock™ PICC Plus Stabilization
Device [Product ID: VPPDFP]; Bard Medical, Covington,
GA, USA) placed outside of the dressing area as per hos-
pital policy [21–24]. Group 2 received a polyurethane with
absorbent lattice pad (PAL) dressing (OPSITE™ Post-Op
Visible® 9 cm x 10 cm [Product ID: 6600842] [25]; Smith
and Nephew, Hull, UK) and adhesive, non-woven tape
(Fixomull® 10 cm x 10 cm [Product ID: 02037-00] ; BSN
Medical, Hamburg, Germany). The PAL dressing “sand-
wiches” the PICC with two strips of polyurethane (one on
top and one underneath the PICC) to provide additional se-
curement. Group 3 received a combination securement
dressing (CSD) (Sorbaview SHIELD® 9.5 cm x 14 cm [Prod-
uct ID: SV353UDT-6] [26]; Centurion, Williamston, MI,
USA), which has increased securement under and over the
PICC and an absorbent layer. Group 4 received tissue adhe-
sive (TA) (Histoacryl Blue® [Product ID: TS1050044FP] [27,
28]; B Braun Surgical, Rubi, Spain), two to three drops at
the insertion site and under the PICC wings and allowed 30
s to dry, plus SPU as above. With the exception of the TA
group, all groups used chlorhexidine-gluconate impreg-
nated discs (CHG) at the PICC insertion site (Bio-
patch® [Product ID: 4151]; Johnson and Johnson, NJ, USA).
The study groups were referred to as SPU+ SSD+CHG,
PAL +CHG+Tape, CSD+CHG, and TA+ SPU, respect-
ively. Figure 1 shows all dressing and securement methods.
Insertion and care of the PICC and securements
PICCs were inserted by clinical nurses, radiographers and
radiologists following skin decontamination with swab
sticks impregnated with 2% chlorhexidine gluconate and
70% isopropyl alcohol. If patients had a known skin allergy
to this product, skin decontamination was performed using
Betadine solution (containing 10% povidone-iodine). The
ultrasound/fluoroscopy-guided insertion and chest x-ray tip
confirmation techniques were used. Personnel performing
the insertion or ReNs applied the allocated products at inser-
tion or within 24 hours. SmartSite® needleless connectors
were applied as standard to all PICCs. All clinical nurses and
ReNs at the study site must achieve clinical competencies in
PICC management to perform dressing changes, as per hos-
pital policy. All clinical nurses, radiographers, radiologists,
and ReNs involved in the study were equally trained in dress-
ing application and removal in all intervention groups. The
ReNs provided step-by-step written and verbal instructions
to all healthcare professionals involved in the study on apply-
ing and removing dressings in all intervention groups, and
were available to provide assistance in changing dressings
during business hours. Study products were changed by clin-
ical nurses with or without the study ReN weekly, and as
needed, to remain clean, dry and intact [23]. TA was re-
moved with Remove© wipes (Smith and Nephew) then re-
applied at each dressing change. In this pragmatic trial,
clinical nurses added strips of non-sterile paper tape to infu-
sion tubing and additional securement products at their dis-
cretion, and these were recorded by ReNs.
For suspected CABSI, clinical (not research) staff ordered
peripheral blood cultures with or without PICC-drawn
qualitative (not quantitative) blood cultures, as per usual
practice [29]. PICC blood culture, entry site and tip cultures
were taken at clinician discretion. Blood cultures were not
taken routinely as they provide no added diagnostic value
to those taken on clinical suspicion of infection [30, 31].
Data collection
Data were directly entered into Research Electronic Data
CAPture (REDCap; Vanderbilt University, hosted by
Griffith University) by ReNs using a tablet computer. Base-
line data were collected on demographic and clinical
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characteristics (age, gender, diagnosis, immunosuppression,
infection status, co-morbidities, weight, skin type/integrity,
hand dominance (right/left)); and on device characteristics
(location, side (right/left), number of lumens, inserter, num-
ber of attempts, skin preparation, and infusates). ReNs vis-
ited active patients daily to assess protocol compliance, and
to document endpoints and adverse events. PICC removal
data were collected on the reason for PICC removal, site
complications, dwell time, length of stay, mortality, level of
consciousness, mobility, and cognitive state. Data on prod-
uct residue, rash, blister, itchiness, or tearing of skin on
dressing removal were recorded.
We reviewed cases of CABSI for CRBSI using the dif-
ferential time to positivity, or matched tip/blood culture
criteria [32]. All microbiology analysis was by blinded
scientists, and endpoints were adjudicated by a blinded
infectious diseases physician. Product residue, rash, blis-
ter, itchiness, or tearing of skin on dressing removal
Fig. 1 Dressing and securement methods for each study group. SPU + SSD, standard polyurethane dressing plus a sutureless securement device
plus chlorhexidine-gluconate impregnated discs; PAL + CHG + Tape, polyurethane with absorbent lattice pad adhesive plus non-woven tape plus
chlorhexidine-gluconate impregnated discs; CSD + CHG, combination securement dressing plus chlorhexidine-gluconate impregnated discs; TA + SPU,
tissue adhesive plus standard polyurethane dressing
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were recorded. A purposive sample of 20 clinical staff
(who applied or removed study products) participated in
brief semi-structured interviews about the strengths and
weaknesses of any study products that they had used
during the trial.
Outcomes
Feasibility outcomes were recruitment, safety, and ac-
ceptability of the interventions. The primary endpoint
was PICC failure, a composite of reasons for premature
PICC removal (i.e. PICC could no longer be used for re-
quired therapy). This was recorded dichotomously per
patient (yes/no) and expressed as incidence rates per
1000 PICC days, to account for the varying PICC dwell
durations and thus exposure to the chance of developing
a failure outcome. PICC failure is a common measure
in vascular access research [5] and includes: (1) CABSI
(laboratory-confirmed bloodstream infection not related
to another site) [33]; (2) local infection (positive tip/skin
colonisation around the exit site, purulent discharge, or
redness extending 1 cm beyond the site that prompts the
clinician to order removal and commence antimicrobial
therapy); (3) dislodgement: total – the PICC lumen tip
completely leaves the vein; partial – the PICC tip is no
longer in the superior vena cava (diagnosed by chest x-ray,
leakage from the site on injection, or clinician diagnosis);
post-insertion change in PICC length (catheter marking) at
the hub; (4) occlusion: ≥1 lumen unable to be flushed/aspi-
rated, as diagnosed by clinician; [34] and/or (5) PICC frac-
ture: visible fracture, leak, split, or other damage to the
PICC material as diagnosed by the treating clinician.
Secondary outcomes were each type of PICC failure;
dressing/securement failure (early replacement before
7 days as loose, soiled, or missing); PICC dwell time and
first dressing/securement dwell time: hours from insertion/
application until removal; skin complications and phlebitis
indicators; purchase costs of study products for one appli-
cation/per patient use of each dressing/securement (does
not include labour costs). Patient satisfaction data were
collected upon completion of the study (0 = totally dissatis-
fied; 10 = totally satisfied). Nurses who removed the
study dressing at the completion of the study were
asked to rate the degree of difficulty in completing
this task (0 = extremely difficult; 10 = extremely easy).
Statistical analysis
Feasibility outcomes and qualitative data were reported
descriptively. All randomised patients were analyzed
using intention-to-treat analysis. Patients were the unit
of measurement (one PICC per patient). Prior to analysis
(Stata 14.1, Stata-Corp), outlying figures, missing data,
and implausible data were cleaned, and a random 5%
source data rechecked. Missing values were not imputed.
Incidence rates per 1000 PICC days and rate ratios were
calculated to test differences between groups, with com-
parisons over time using Kaplan-Meier survival curves
and log-rank tests. Secondary endpoints were reported
using frequencies, proportions or mean (SD), or median
(interquartile range). Cost data per dressing change were
reported descriptively. Cox regression was used to test
the effect of covariates (variables <0.2 on univariable
analysis were included in the multivariable model), and
the effect of study group on PICC failure. Continuous
variables (e.g. age) were centred over means and correla-
tions between covariates were checked. The categorical
covariates were re-grouped for the Cox multivariable
analysis, by merging small (n < 20) categories into neigh-
bouring categories with similar effects, or similarly mer-
ging categories to explore where the significant cutoff
point was. The ten-events-per-variable rule was consid-
ered and the final model derived by manual backward
deletion of covariates at p ≥ 0.05 (keeping study group in
the model). The proportional-hazards assumption was
checked using the Schoenfeld residuals on the final mul-
tivariable model. The final multivariable model breached
our own self-imposed ten-events-per-variable rule,
which was done with the intention to inform future
studies (otherwise potentially interesting associations
would not show up), and was deemed acceptable for a
pilot study [35]. No adjustment was made for multiple
comparisons. P < 0.05 was considered significant.
Results
Feasibility outcomes and participant characteristics
Of 715 patients screened for eligibility, 124 were recruited
and randomised; the outcomes of 121 patients (98%) were
analyzed with the exception of 3 patients unable to have a
PICC inserted or who had no further study involvement
(Fig. 2). One patient (CSD + CHG group) withdrew from
the study but allowed censored outcome data to be in-
cluded in the analysis. At baseline, the groups were gener-
ally similar in demographic and clinical factors (Table 1).
Participants in all groups, reported mean satisfaction
scores >8 out of 10 (Table 2). Clinicians reported PAL +
CHG+Tape as high risk for PICC dislodgement at both
insertion and removal in each of the five patients studied,
due to the seamless “sandwich” component of the dress-
ing, with one PICC dislodged. Due to clinical staff con-
cern, recruitment to this group ceased. The TA + SPU
technique was found problematic after repeated applica-
tions (at each dressing replacement) with build-up occur-
ring on the PICC; this was not observed after the initial
application. There was no negative feedback on the CSD.
Many patients in all groups received additional PICC
reinforcement at the discretion of clinical staff; this was
permitted as this was a pragmatic trial (Fig. 2). A total of
1132 catheter-days were studied, with 6.9 days median
PICC dwell per patient.
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Primary outcomes
Catheter failure rate was highest in PAL +CHG+Tape (1/
5, 20%), and lowest in CSD +CHG (3/42, 7%), with SPU +
SSD +CHG (control) and TA + SPU having failure rates of
10% (4/39) and 9% (3/35), respectively (Table 2). Incident
rates per 1000 catheter-days were 17, 9, 9, and 10, respect-
ively (log-rank test, p = 0.980) (Table 2 and Fig. 3). The hy-
pothesis of no difference in failure over time was not
rejected. The adjusted hazard ratio (HR) of PICC failure
compared to control was one third lower in CSD +CHG
(HR = 0.64, 95% CI = 0.14–2.92), similar in TA + SPU (HR
= 1.07, 95% CI = 0.24–4.83) and increased fourfold in PAL
+ CHG+Tape (HR = 4.17, 95% CI = 0.36–48.4) (Table 3).
PICC failure was approximately 90% less likely in women
than in men (HR = 0.10, 95% CI = 0.01–0.87, p = 0.037),
but increased fourfold in patients with three or more co-
morbidities, compared to those with one or no comorbidi-
ties (HR = 4.62, 95% CI = 1.04–20.4, p < 0.005).
Secondary outcomes
Secondary outcomes are reported in Table 2. PICC fail-
ure was most commonly due to dislodgement, affecting
6% of all patients. Three participants developed CABSI
(CSD + CHG, n = 2; TA + SPU, n = 1). Of these, one
(CSD + CHG group) was confirmed as CRBSI by differ-
ential time to positivity of peripheral and PICC-drawn
blood cultures [32]. There were no local infections. Me-
dian days to first dressing change was shortest in PAL +
CHG+Tape (0.9 days, 95% CI = 0.41–2.60), and longest in
CSD +CHG (1.8 days, 95% CI = 0.53–5.45). Average
dressing dwell was shortest in the TA + SPU and
CSD +CHG groups (3.4 days and 3.5 days, respectively).
The purchase costs (AUD 2015) of dressing and secure-
ments per one application/per patient for all applica-
tions were: AU$18.52/AU$34.66 (SPU + SSD + CHG);
AU$18.36/AU$33.05 (PAL + CHG + Tape), AU$16.33/
AU$20.61 (CSD +CHG) and AU$18.82/AU$32.80 (TA +
SPU).
Skin complications as a composite outcome of any
rash, blister, itchiness, skin tear, or bruising at device re-
moval ranged from 20% to 36% across study groups
(Table 2). TA + SPU had the most participants with phle-
bitis indicators including pain (n = 5, 14%), tenderness
(n = 10, 28%), erythema (n = 11, 31%), swelling (n = 9, 26%),
and purulent discharge (n = 2, 6%) (Table 2). Nursing staff
reported that SPU+ SSD +CHG products were the easiest
to remove (mean = 8.44 out of 10) and PAL +CHG+Tape
were the most difficult (mean = 5.00 out of 10).
Fig. 2 Consolidated Standards of Reporting Trials (CONSORT) flow chart. SPU + SSD, standard polyurethane dressing plus a sutureless securement
device plus chlorhexidine-gluconate impregnated discs; PAL + CHG + Tape, polyurethane with absorbent lattice pad adhesive plus non-woven
tape plus chlorhexidine-gluconate impregnated discs; CSD + CHG, combination securement dressing plus chlorhexidine-gluconate impregnated
discs; TA + SPU, tissue adhesive plus standard polyurethane dressing
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Table 1 Participant, PICC insertion and treatment characteristics at randomisation*
Group 1
SPU + SSD+ CHG
Group 2
PAL+ CHG + Tape
Group 3
CSD+ CHG
Group 4
TA + SPU
At recruitment (N = 124) (n = 40) (n = 5) (n = 43) (n = 36)
Age (years)a 56 (16) 63 (20) 57 (15) 54 (18)
Sex (male) 25 (62) 2 (40) 27 (63) 25 (69)
Overweight/obese (n = 102) 20 (62) 2 (50) 21 (58) 16 (53)
Skin integrity:
- good 13 (32) 1 (20) 13 (30) 14 (39)
- fair 21 (52) 3 (60) 26 (60) 18 (50)
- poor 6 (15) 1 (20) 4 (9) 4 (11)
Skin type (white) 32 (80) 3 (60) 30 (70) 26 (72)
Comorbidities 31 (78) 4 (80) 32 (74) 21 (58)
- none 3 (8) 1 (20) 4 (9) 5 (14)
- one 6 (15) 0 (0) 7 (16) 10 (28)
- two 6 (15) 1 (20) 7 (16) 5 (14)
- three 6 (15) 1 (20) 6 (14) 2 (6)
- four or more 19 (48) 2 (40) 19 (44) 14 (39)
Diagnosis:
- medical 10 (25) 1 (20) 14 (33) 10 (28)
- surgical emergency 9 (22) 2 (40) 11 (26) 8 (22)
- surgical elective 8 (20) 0 (0) 6 (14) 8 (22)
- haematology 4 (10) 1 (20) 4 (9) 7 (19)
- oncology 5 (12) 1 (20) 3 (7) 3 (8)
- surgical oncology 4 (10) 0 (0) 5 (12) 0 (0)
Leucocytes lowb 1 (2) 0 (0) 0 (0) 0 (0)
Infection (any) 23 (58) 4 (80) 24 (56) 20 (56)
Antibiotic therapy: 31 (78) 5 (100) 30 (70) 28 (78)
- intravenous 31 (78) 3 (60) 29 (67) 27 (75)
- oral 1 (2) 3 (60) 8 (19) 4 (11)
At PICC insertion (N = 121) (n = 39) (n = 5) (n = 42) (n = 35)
PICC type (n = 120):
- basilic 35 (92) 5 (100) 34 (81) 33 (94)
- brachial 2 (5) 0 (0) 5 (12) 1 (3)
- cephalic 1 (3) 0 (0) 3 (7) 1 (3)
Subsequent insertion 11 (28) 0 (0) 12 (29) 8 (23)
Inserted by:
- nurse 36 (92) 5 (100) 35 (83) 31 (89)
- radiographer 3 (8) 0 (0) 7 (17) 3 (9)
- doctor 0 (0) 0 (0) 0 (0) 1 (3)
Insertion method:
- ultrasound 27 (69) 5 (100) 32 (76) 22 (63)
- ultrasound, fluoroscopy 12 (31) 0 (0) 10 (24) 13 (37)
Multiple insertion attempts 5 (13) 1 (20) 3 (7) 5 (14)
Hair, before insertion: 4 (10) 0 (0) 10 (24) 8 (23)
- if yes, clippedc 2 - 1 2
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Discussion
Feasibility outcomes were generally positive with 10 pa-
tients randomised on average each month, if patients
from all specialties (medical, surgical, and cancer care)
were included. Attrition was low at 1/121 (0.8%) and
there were no missing data for the primary endpoint.
The standard care (control), CSD + CHG group and the
TA + SPU group (with use at insertion only) appear feas-
ible and acceptable for future trials. The CSD + CHG
group, with the “two-in-one” CSD, had the least failure
(7%); a larger trial would be needed to detect statistical
differences. Purchase costs per patient in this group
were 40% less than for controls and future trials should
now assess cost-effectiveness. Both clinician satisfaction
scores and qualitative feedback indicated CSD was the
easiest product to apply and remove. While the PAL
dressing was anticipated as suitable for PICCs due to its
absorbency, nurses experienced difficulty in removing
the dressing without dislodging the PICC. This study
indicated that its drain dressing design was not condu-
cive to PICCs, which require more frequent dressing
changes. Recruited to this arm ceased early due to these
concerns and thus further testing was not feasible. We
do not recommend this product for PICCs.
Although TA + SPU was viewed positively by clinicians
to control haemostasis, repeated TA use at each dressing
replacement remained easily removed from skin, but ac-
cumulated on the polyurethane catheter, threatening skin
injury. Manual removal of TA from PICCs increased the
risk of dislodgement, and was time-consuming. While TA
has potential benefits at insertion, its use for repeated
dressings during PICC dwell was not feasible. Adverse
skin complications and phlebitis were most common in
the TA group, with pain and tenderness seemingly caused
by skin “tugging” with pressure on the PICC. This product
requires further testing to determine the effectiveness of
applying TA at the initial application only.
The overall failure incidence (9%) was lower than
reported in similar adult populations [4, 5], primarily
because we censored follow up at a maximum of 4 weeks
post insertion. If we had followed patients for the entire
PICC dwell (which can be many months), more failures
may have been detected. In addition, the enhanced
monitoring (e.g. daily inspection) provided by the ReNs
(experienced nurses with an expertise in managing vas-
cular access devices) in a trial setting and assistance to
clinical staff with changing some of the dressings may
have reduced failure incidence.
Table 1 Participant, PICC insertion and treatment characteristics at randomisation* (Continued)
Group 1
SPU + SSD+ CHG
Group 2
PAL+ CHG + Tape
Group 3
CSD+ CHG
Group 4
TA + SPU
Inserted on dominant side 20 (51) 3 (60) 22 (52) 19 (54)
Number of lumens (two)d 27 (69) 1 (20) 31 (74) 23 (66)
Treatment (N = 121) (n = 39) (n = 5) (n = 42) (n = 35)
IV fluids/medicationse:
- fluid continuous 29 (74) 4 (80) 31 (74) 31 (89)
- normal saline flush 11 (28) 2 (40) 5 (12) 3 (9)
- chemotherapy 3 (8) 1 (20) 3 (7) 6 (17)
- PN (non-lipid) 6 (15) 0 (0) 8 (19) 5 (14)
- lipids 7 (18) 0 (0) 6 (14) 4 (11)
- blood products 11 (28) 2 (40) 7 (17) 8 (23)
- antibiotics 31 (79) 2 (40) 28 (67) 29 (83)
- heparin, continuous 5 (13) 0 (0) 2 (5) 5 (14)
Patient confused/agitated/drowsy (n = 119)f 1 (3) 0 (0) 6 (15) 4 (12)
Ventilated/intubated (n = 119)f 1 (3) 0 (0) 1 (2) 0 (0)
Independently mobile (n = 119)f 22 (56) 3 (60) 25 (61) 21 (62)
Other VAD in situf 2 (5) 0 (0) 9 (21) 9 (26)
*Data presented on 124 randomised patients and 121 inserted peripherally inserted central catheters (PICCs); number (percentage) shown unless otherwise noted.
Frequencies may not add up to group size (and frequencies to 100%) due to missing data
SPU simple polyurethane dressing, SSD sutureless securement device, CHG chlorhexidine gluconate-impregnated discs, PAL polyurethane with absorbent lattice
pad dressing, CSD combination securement dressing, TA tissue adhesive, VAD vascular access device, PN parenteral nutrition
aMean (standard deviation) shown
bAbsolute value <1000 per microlitre
cFrequencies shown only
dOther categories omitted
eReceived at any time during the study period
fAt device removal
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Table 2 Study outcomes (n = 121)
Group 1
SPU + SSD + CHG
(n = 39)
Group 2
PAL + CHG + Tape
(n = 5)
Group 3
CSD + CHG
(n = 42)
Group 4
TA + SPU
(n = 35)
PICC failure (per patient) 4 (10%) 1 (20%) 3 (7%) 3 (9%)a
Incidence rate (95% CI)b 9.03 (3.39–24.1) 17.4 (2.45–123) 9.43 (3.04–29.2) 9.57 (3.09–29.7)
Rate ratio (95% CI) referent 1.92 (0.04–19.4) 1.04 (0.15–6.17) 1.06 (0.16–6.27)
Log-rank test (p value) referent 0.629 0.905 0.939
Catheter-days 443 58 318 313
PICC dwell time (days)c 8.94 (3.13, 20.9) 9.99 (7.23, 16.1) 5.56 (4.11, 9.97) 7.11 (4.00, 14.8)
Secondary outcomes:
- CABSI 0 (0%) 0 (0%) 2 (5%) 1 (3%)
- dislodgement 4 (10%) 1 (20%) 0 (0%) 2 (6%)
- occlusion 0 (0%) 0 (0%) 1 (2%) 0 (0%)
- fracture 0 (0%) 1 (20%) 0 (0%) 1 (3%)
- 1st secdev life <7d (n = 116) 26 (72%) 4 (80%) 25 (61%) 25 (74%)
- patient satisfactiond,e 8.79 (1.67) 9.25 (1.50) 9.17 (1.48) 8.17 (2.02)
- difficulty of removald,f 8.44 (2.14) 5.00 (4.36) 7.97 (2.38) 6.04 (2.74)
Skin complicationg 12 (30%) 1 (20%) 9(21%) 13 (36%)
Phlebitis indicators (n = 119):h
- pain ≥2/10 2 (5%) 0 (0%) 4 (10%) 5 (14%)
- tenderness ≥2/10 5 (13%) 0 (0%) 8 (20%) 10 (28%)
- erythema (any) 7 (18%) 0 (0%) 8 (20%) 11 (31%)
- swelling (any) 1 (3%) 1 (20%) 3 (7%) 9 (26%)
- purulent discharge 0 (0%) 1 (20%) 1 (2%) 2 (6%)
- any 11 (29%) 2 (40%) 17 (41%) 18 (51%)
Serious adverse events:
- death 0 (0%) 0 (0%) 1 (2%) 2 (6%)
- positive blood culture 0 (0%) 0 (0%) 2 (5%) 2 (6%)
- other 2 (5%) 0 (0%) 1 (2%) 1 (3%)
Number of dressing changes: 72 8 52 60
- Incidence rateb 163 139 163 191
Dressing/secdev life:
- days to first changec 1.71 (0.66, 3.38) 0.94 (0.41, 2.60) 1.83 (0.53, 5.45) 1.49 (0.56, 3.44)
- daysd 3.68 (1.77) 5.21 (2.86) 3.53 (1.98) 3.41 (1.52)
Reason for change (n = 189)i:
- routine 45 (62%) 3 (38%) 27 (53%) 19 (33%)
- dressing lifting 19 (26%) 4 (50%) 11 (22%) 27 (47%)
- sweating 4 (6%) 0 (0%) 0 (0%) 2 (3%)
- leakage 2 (3%) 2 (25%) 1 (2%) 0 (0%)
- bleeding 12 (17%) 5 (62%) 11 (21%) 10 (17%)
- unknown 0 (0%) 0 (0%) 0 (0%) 1 (2%)
- other 18 (25%) 2 (25%) 20 (39%) 28 (48%)
Number (percentage) shown unless otherwise noted
SPU simple polyurethane dressing, SSD sutureless securement device, CHG chlorhexidine gluconate-impregnated discs, PAL polyurethane dressing with absorbent lattice
pad, CSD combination securement dressing, TA tissue adhesive, PICC peripherally inserted central catheter; CABSI catheter associated bloodstream infection, secdev se-
curing device, VAD vascular access device
aOne patient had two forms of failure (dislodgement and breakage) but was only counted once
bIncidence rate per 1000 catheter-days
cMedian and interquartile range shown as 25th and 75th percentiles
dMean and standard deviation
ePatient self-report, 0 = completely dissatisfied, …, 10 = completely satisfied;
fNurse rating of difficulty when removing the product: 0 = very difficult, …, 10 = very easy; gAny of rash, blister, itchiness, skin tear, or bruising at device removal; values
may not add up to total due to rounding, percentages were calculated with the number of non-missing values in the denominator
hObserved at any time during study
iDenominator: number of dressing changes in that group; frequencies may not add up to group size (and frequencies to 100%) due to missing data
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Table 3 Cox regression of PICC failure (n = 121)
Univariable
HR (95% CI)
Multivariable
HR (95% CI)
Intervention (referent (ref) SPU + SSD + CHG):
- PAL + CHG + Tape 1.60 (0.18–14.4) 4.17 (0.36–48.4)
- CSD + CHG 1.06 (0.23–4.83) 0.64 (0.14–2.92)
- TA + SPU 1.04 (0.23–4.67) 1.07 (0.24–4.83)
Age (one year older) 1.02 (0.97–1.06) –
Female sex (ref. male) 0.15 (0.02–1.15)* 0.10 (0.01–0.87)**
Overweight/obese (ref. other) 1.70 (0.47–6.20) –
Comorbidities (ref. up to 3) 3.37 (0.89–12.8)* 4.62 (1.04–20.4)**
Skin integrity fair/poor (ref. good) 2.00 (0.43–9.28) –
Skin type brown (ref. white) 0.67 (0.14–3.12) –
Diagnosis –
- oncology (ref. surgical) 1.50 (0.43–5.20) –
- medical (ref. surgical) 0.36 (0.04–3.09) –
Gastrointestinal surgery (ref. other type) 0.90 (0.16–4.94) –
Drain (ref. none) 2.10 (0.61–7.19) –
Wound (ref. none) 0.91 (0.24–3.43) –
Infection (ref. none) 1.14 (0.33–3.91) –
IV therapy (ref. none) a –
Antibiotic therapy (ref. none) 0.75 (0.20–2.84) –
U/S guided insertion with fluoroscopy (ref. U/S guided) 2.34 (0.71–7.70)* b
Insertion on dominant side (ref. false) 1.07 (0.32–3.51) –
Lumens (one more) a –
Subsequent device (ref. false) 2.68 (0.80–8.92)* b
Device length (1 cm longer) 1.00 (0.91–1.11) –
Baseline observations were used; a = cannot be calculated; b = removed during variable selection at p ≥ 0.05; hyphen = not entered into the multivariate model
PICC peripherally inserted central catheter, HR hazard ratio, CI confidence interval, SPU simple polyurethane dressing, SSD sutureless securement device, CHG chlorhexidine
gluconate-impregnated discs, PAL polyurethane with absorbent lattice pad dressing, CSD combination securement dressing, TA tissue adhesive, U/S ultrasound
*p value <0.20; **p value <0.05
Fig. 3 Kaplan-Meier survival estimates from peripherally inserted central catheter (PICC) failure, by study group; log-rank test, p = 0.98; n = 121.
SPU + SSD, standard polyurethane dressing plus a sutureless securement device plus chlorhexidine-gluconate impregnated discs; PAL + CHG + Tape,
polyurethane with absorbent lattice pad adhesive plus non-woven tape plus chlorhexidine-gluconate impregnated discs; CSD + CHG, combination
securement dressing plus chlorhexidine-gluconate impregnated discs; TA + SPU, tissue adhesive plus standard polyurethane dressing
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The most common failure type (6% of all PICCs) was
dislodgement, confirming that this is an ongoing, signifi-
cant problem and that PICC dressing and securement is a
priority area for improvement. The multivariable analysis
identified two significant factors (male gender, and three
or more comorbidities) associated with PICC failure. Male
gender may increase risk due to men being more hirsute,
which can disrupt dressing adhesiveness [36] and having
more muscle movement. In spite of the non-modifiable
nature of these two risk factors, clinicians should pay add-
itional attention in ensuring best insertion, monitoring
and maintenance practice in men, and those with three or
more comorbidities.
Almost one in three patients (29%) had skin complica-
tions (rash, blister, itchiness, skin tear, or bruising), and al-
though comparable between treatment arms, this clearly
demonstrates the need to improve comfort and skin health
in patients with PICCs. Few patients (n = 3) developed
CABSI and no serious adverse events were caused by the
study interventions. Whilst as a pragmatic trial it was not
precluded, we did not expect clinical nurses to add add-
itional tapes, dressings, and securements to the extent
that was reported (Fig. 1). Bandage, and additional ad-
hesives (typically non-sterile paper tape) were frequent
additions in all groups. While reasons for each add-
itional product application were not collected, this
might reflect clinicians delaying replacements of the
primary dressing (e.g. if a corner was loose) or lacking
confidence in its effectiveness. Future pragmatic trials
should collect reasons for additional product use and
undertake comprehensive cost-benefit analyses of these
products.
To our knowledge, this is the first pilot RCT to investi-
gate these three novel securement and dressing interven-
tions in adult patients with PICCs. We acknowledge the
design limitations inherent in a pilot RCT with a small
sample size. Future RCTs would need 3213 patients/group
to test a hypothesis of 10% versus 8% failure, or 1356
patients/group to compare 10% versus 7% failure (sta-
t.ubc.ca/~rollin/stats/ssize/b2.html, 80% power, p = 0.05).
A comprehensive cost-effectiveness analysis is also needed
in future work; in this study we provided initial costs asso-
ciated with consumables. We did not include thrombosis
in the PICC failure endpoint, and although none occurred,
we plan to include this in future trials since this is a grow-
ing concern in PICCs [8] that may be impacted by poor
securement. Despite these limitations, this study demon-
strated the safety and feasibility of two regimens and
provides preliminary data to inform the design of a
larger RCT of CSD +CHG, and TA + SPU (with TA at in-
sertion only) versus standard care (used in this study), to
improve PICC outcomes. PICC failure has significant pa-
tient and health system costs, it is important that clini-
cians have evidence available on how to effectively prevent
these complications and implement policy decisions about
PICC dressing and securement.
Conclusions
CSD+CHG and TA+ SPU (but not PAL +CHG+Tape)
are feasible interventions to be tested against controls in a
full-scale RCT, to inform measures to prevent PICC failure.
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